Godavari Drugs
BSE: GODAVARI · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Godavari Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Godavari Drugs Limited is a Hyderabad-based pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company operates a multi-purpose facility in Maharashtra and serves both domestic and international markets across Asia, Europe, and Latin America.
Business Model
The company generates revenue through the production and sale of bulk drugs, focusing on therapeutic segments such as sulfonamides, fluoroquinolones, and antihistamines. It leverages backward integration and process optimisation to maintain cost-competitiveness in the pharmaceutical manufacturing sector.
Management Commentary
Management focuses on enhancing manufacturing efficiencies and expanding the product range through sustained investment in research and development.
Growth Outlook
Growth is driven by the expansion of the product portfolio and continuous improvements in manufacturing processes. The company aims to strengthen its competitive position in the bulk drug industry through strategic R&D investments.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent and evolving international regulatory standards for pharmaceutical manufacturing.
- Raw Material Price Volatility. Fluctuations in the cost of chemical intermediates and raw materials can significantly impact profit margins.
- Market Competition. The bulk drug industry is highly competitive, requiring constant process innovation to maintain market share.
- Export Dependency. Exposure to international markets introduces risks associated with currency fluctuations and geopolitical trade barriers.
Start your research today
Unlock AI insights, financials, peers and live data on Godavari Drugs and 5,000+ companies — free.
Key Metrics
REVENUE
₹106 Cr
TTM · standalone
NET PROFIT
₹4 Cr
TTM · standalone
EPS
₹5.43
TTM · standalone
RETURN ON EQUITY
7.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
11.1%
TTM · standalone
P/E
22.1x
Q4 FY26 · standalone
EV/EBITDA
13.5x
Q4 FY26 · standalone
EBITDA MARGIN
10.5%
TTM · standalone
NET PROFIT MARGIN
3.9%
Q4 FY26 · standalone
DEBT TO EQUITY
1.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Godavari DrugsGODAVARI | ₹101 Cr | 18.42 | 14.70 | -6.7% | 10.5% | 7.9% | 11.1% | +20.4% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Godavari Drugs
BSE: GODAVARI · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Godavari Drugs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Godavari Drugs Limited is a Hyderabad-based pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company operates a multi-purpose facility in Maharashtra and serves both domestic and international markets across Asia, Europe, and Latin America.
Business Model
The company generates revenue through the production and sale of bulk drugs, focusing on therapeutic segments such as sulfonamides, fluoroquinolones, and antihistamines. It leverages backward integration and process optimisation to maintain cost-competitiveness in the pharmaceutical manufacturing sector.
Management Commentary
Management focuses on enhancing manufacturing efficiencies and expanding the product range through sustained investment in research and development.
Growth Outlook
Growth is driven by the expansion of the product portfolio and continuous improvements in manufacturing processes. The company aims to strengthen its competitive position in the bulk drug industry through strategic R&D investments.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent and evolving international regulatory standards for pharmaceutical manufacturing.
- Raw Material Price Volatility. Fluctuations in the cost of chemical intermediates and raw materials can significantly impact profit margins.
- Market Competition. The bulk drug industry is highly competitive, requiring constant process innovation to maintain market share.
- Export Dependency. Exposure to international markets introduces risks associated with currency fluctuations and geopolitical trade barriers.
Start your research today
Unlock AI insights, financials, peers and live data on Godavari Drugs and 5,000+ companies — free.
Key Metrics
REVENUE
₹106 Cr
TTM · standalone
NET PROFIT
₹4 Cr
TTM · standalone
EPS
₹5.43
TTM · standalone
RETURN ON EQUITY
7.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
11.1%
TTM · standalone
P/E
22.1x
Q4 FY26 · standalone
EV/EBITDA
13.5x
Q4 FY26 · standalone
EBITDA MARGIN
10.5%
TTM · standalone
NET PROFIT MARGIN
3.9%
Q4 FY26 · standalone
DEBT TO EQUITY
1.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26